Cargando…

Contributions of Liquid-Based (Papanicolaou) Cytology and Human Papillomavirus Testing in Cotesting for Detection of Cervical Cancer and Precancer in the United States

OBJECTIVES: Given the recent debate challenging the contribution of cytology in cervical screening, we evaluated results of liquid-based cytology (LBC) and human papillomavirus (HPV) testing in cotesting preceding cervical cancer (CxCa) and precancer diagnoses in a national, heterogeneous population...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaufman, Harvey W, Alagia, Damian P, Chen, Zhen, Onisko, Agnieszka, Austin, R Marshall
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523581/
https://www.ncbi.nlm.nih.gov/pubmed/32637991
http://dx.doi.org/10.1093/ajcp/aqaa074
_version_ 1783588406103638016
author Kaufman, Harvey W
Alagia, Damian P
Chen, Zhen
Onisko, Agnieszka
Austin, R Marshall
author_facet Kaufman, Harvey W
Alagia, Damian P
Chen, Zhen
Onisko, Agnieszka
Austin, R Marshall
author_sort Kaufman, Harvey W
collection PubMed
description OBJECTIVES: Given the recent debate challenging the contribution of cytology in cervical screening, we evaluated results of liquid-based cytology (LBC) and human papillomavirus (HPV) testing in cotesting preceding cervical cancer (CxCa) and precancer diagnoses in a national, heterogeneous population. METHODS: We assessed the results of cotesting, performed by Quest Diagnostics, in 13,633,071 women 30 years and older, tested 2010 to 2018. Cotest results preceding CxCa or precancer diagnoses were analyzed and stratified by histopathology. RESULTS: Among all screening results, 1,615 cotests preceded 1,259 CxCa diagnoses, and 11,164 cotests preceded 8,048 cervical precancer diagnoses. More women who were subsequently diagnosed with CxCa within 1 year were identified by the LBC result than by the HPV result (85.1%, 1,015/1,193 vs 77.5%, 925/1,193). Among all women with CxCa, the overall rate of nondetection was 13.1% (212/1,615) for cotesting results (LBC negative/HPV negative) and this rate increased substantially when testing exceeded 12 months compared to within 1 year prediagnosis of either CxCa or precancer. CONCLUSIONS: Analysis of 9-year cotest results from a national reference laboratory confirms the value of LBC element in cotesting. This supports that LBC/HPV cotesting enhances screening for the identification of CxCa in women 30 years and older, more so than LBC or HPV alone within cotesting.
format Online
Article
Text
id pubmed-7523581
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-75235812020-10-02 Contributions of Liquid-Based (Papanicolaou) Cytology and Human Papillomavirus Testing in Cotesting for Detection of Cervical Cancer and Precancer in the United States Kaufman, Harvey W Alagia, Damian P Chen, Zhen Onisko, Agnieszka Austin, R Marshall Am J Clin Pathol Original Articles OBJECTIVES: Given the recent debate challenging the contribution of cytology in cervical screening, we evaluated results of liquid-based cytology (LBC) and human papillomavirus (HPV) testing in cotesting preceding cervical cancer (CxCa) and precancer diagnoses in a national, heterogeneous population. METHODS: We assessed the results of cotesting, performed by Quest Diagnostics, in 13,633,071 women 30 years and older, tested 2010 to 2018. Cotest results preceding CxCa or precancer diagnoses were analyzed and stratified by histopathology. RESULTS: Among all screening results, 1,615 cotests preceded 1,259 CxCa diagnoses, and 11,164 cotests preceded 8,048 cervical precancer diagnoses. More women who were subsequently diagnosed with CxCa within 1 year were identified by the LBC result than by the HPV result (85.1%, 1,015/1,193 vs 77.5%, 925/1,193). Among all women with CxCa, the overall rate of nondetection was 13.1% (212/1,615) for cotesting results (LBC negative/HPV negative) and this rate increased substantially when testing exceeded 12 months compared to within 1 year prediagnosis of either CxCa or precancer. CONCLUSIONS: Analysis of 9-year cotest results from a national reference laboratory confirms the value of LBC element in cotesting. This supports that LBC/HPV cotesting enhances screening for the identification of CxCa in women 30 years and older, more so than LBC or HPV alone within cotesting. Oxford University Press 2020-07-08 /pmc/articles/PMC7523581/ /pubmed/32637991 http://dx.doi.org/10.1093/ajcp/aqaa074 Text en © American Society for Clinical Pathology, 2020. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Articles
Kaufman, Harvey W
Alagia, Damian P
Chen, Zhen
Onisko, Agnieszka
Austin, R Marshall
Contributions of Liquid-Based (Papanicolaou) Cytology and Human Papillomavirus Testing in Cotesting for Detection of Cervical Cancer and Precancer in the United States
title Contributions of Liquid-Based (Papanicolaou) Cytology and Human Papillomavirus Testing in Cotesting for Detection of Cervical Cancer and Precancer in the United States
title_full Contributions of Liquid-Based (Papanicolaou) Cytology and Human Papillomavirus Testing in Cotesting for Detection of Cervical Cancer and Precancer in the United States
title_fullStr Contributions of Liquid-Based (Papanicolaou) Cytology and Human Papillomavirus Testing in Cotesting for Detection of Cervical Cancer and Precancer in the United States
title_full_unstemmed Contributions of Liquid-Based (Papanicolaou) Cytology and Human Papillomavirus Testing in Cotesting for Detection of Cervical Cancer and Precancer in the United States
title_short Contributions of Liquid-Based (Papanicolaou) Cytology and Human Papillomavirus Testing in Cotesting for Detection of Cervical Cancer and Precancer in the United States
title_sort contributions of liquid-based (papanicolaou) cytology and human papillomavirus testing in cotesting for detection of cervical cancer and precancer in the united states
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523581/
https://www.ncbi.nlm.nih.gov/pubmed/32637991
http://dx.doi.org/10.1093/ajcp/aqaa074
work_keys_str_mv AT kaufmanharveyw contributionsofliquidbasedpapanicolaoucytologyandhumanpapillomavirustestingincotestingfordetectionofcervicalcancerandprecancerintheunitedstates
AT alagiadamianp contributionsofliquidbasedpapanicolaoucytologyandhumanpapillomavirustestingincotestingfordetectionofcervicalcancerandprecancerintheunitedstates
AT chenzhen contributionsofliquidbasedpapanicolaoucytologyandhumanpapillomavirustestingincotestingfordetectionofcervicalcancerandprecancerintheunitedstates
AT oniskoagnieszka contributionsofliquidbasedpapanicolaoucytologyandhumanpapillomavirustestingincotestingfordetectionofcervicalcancerandprecancerintheunitedstates
AT austinrmarshall contributionsofliquidbasedpapanicolaoucytologyandhumanpapillomavirustestingincotestingfordetectionofcervicalcancerandprecancerintheunitedstates